Caitlin Gibson, PharmD, BCPS
Education & Experience:
I received my PharmD from the University of Texas at Austin. I completed a PGY-1 Pharmacy Residency at the Veterans Affairs North Texas Health Care System/Texas Tech University Health Sciences Center School of Pharmacy. I then completed a PGY-2 specialty residency in Internal Medicine at Indiana University Health/Butler University College of Pharmacy and Health Sciences. I joined the faculty at UNT SCP in 2014 as a clinical faculty member. I spend 40% of my time working and teaching as a clinical pharmacist at Medical City Arlington, where I provide team-based care to patients admitted to the Cardiovascular ICU and Telemetry units.
Teaching Areas & Interests:
My primary teaching assignments include teaching and directing the Renal and Cardiovascular Integrated Pharmacotherapy courses at UNT. I also co-direct an Advanced Cardiovascular elective for P3 students. I am also involved in Interprofessional Education on campus. I take P4 students on Acute Care (Internal Medicine) and Cardiology rotations at my practice site, Medical City Arlington. I also precept the Medical City Arlington PGY1 resident on their Academia, Internal Medicine, and Cardiology rotations.
Professional Activities & Awards:
I am an active member of the American College of Clinical Pharmacy (ACCP), American Association of Colleges of Pharmacy (AACP), Phi Delta Chi Professional Pharmacy Fraternity, and Texas Society of Health-System Pharmacists (TSHP). I am also a member of Phi Lambda Sigma and Rho Chi. I serve as primary advisor for the UNT Chapters of Phi Delta Chi and Rho Chi Pharmaceutical Honor Society. I was the 2015-2016 recipient of the UNT Pharmacotherapy “Faculty of the Year” teaching award, and the 2018 recipient of the M.E.T. Award for “Outstanding Junior Faculty Achievement.”
My primary areas of scholarly interest include cardiovascular disease and educational research. I have published several times in the area of anticoagulation, with a specific interest in the feasibility, effectiveness, and safety of direct oral anticoagulants in real-life practice. I am currently completing a prospective clinical study comparing two different deep vein thrombosis dosing strategies in morbidly obese patients. I am also interested in health disparities in cardiovascular disease and treatments and well as mitigating post-operative complications after coronary artery bypass graft surgery. My education research has centered around cultural competency and bringing simulation activities to the classroom.
Gibson CM, Smith CB, Scalese M. Assessment of apixaban prescribing patterns for non-valvular atrial fibrillation in hospitalized patients. Ann Pharmacother. 2018; 52:54-59.
Gibson CM, Basto AN, Howard ML. Direct oral anticoagulants in cardioversion: a review of current evidence. Ann Pharmacother. 2018;52:277-284.
Gibson CM, Davis S, Bradford D. Examining the use of sodium nitroprusside in coronary artery bypass grafting: is the benefit worth the cost? Hosp Pharmacy. 2017; 52(7):502-7.
Gibson CM, Finks S. Edoxaban: How does the newest agent fit into the DOAC landscape? Am J Med. 2017; 130(8):900-906.
Gibson CM, Elrod S. Student versus residency program perceptions of a high-quality PGY1 residency applicant. Curr Pharm Teach Learn. 2017. ePub ahead of print. DOI:10.1016/j.cptl.2017.10.006.
This page was last modified on October 19, 2018